U.S. Major Pharmaceuticals

In a report focusing on U.S. pharmaceuticals, Citi reported that the “U.S. Major Pharma group is outperforming the S&P by ~140 bps (+8.2% vs. +6.8% for S&P). We expect solid pipeline progress to continue to drive outperformance."